Belen Pilo de la Fuente
Interquartile rangeCancerInternal medicineProspective cohort studyMedical recordAdverse effectHazard ratioDimethyl fumarateLeiomyosarcomaMalignancyMultiple sclerosisExpanded Disability Status ScalePopulationPharmacotherapyBreast cancerMedicineCohort
2Publications
0Citations
Publications 2
Newest
Abstract Background Potential increase of cancer incidence is one of the main safety concerns of the disease-modifying therapies employed in Multiple Sclerosis (MS). Objective : Detailed description of patients who developed cancer among a prospective cohort of Spanish MS patients on dimethyl fumarate (DMF) treatment. Methods We describe patients who developed cancer among a cohort of 886 MS patients on DMF treatment (2681 patient-years), with a median time of exposure of 39.5 months (IQR 23-51....
Source
#2Julia SabinH-Index: 1
#3Victoria GalanH-Index: 4
Last. Yolanda AladroH-Index: 7
view all 25 authors...
BACKGROUND Dimethyl fumarate (DMF) has demonstrated efficacy in phase III studies. However, real-world data are still limited. OBJECTIVE The objective of this study was to describe the profile of patients who receive DMF and to assess the effectiveness of DMF regarding relapses, disability progression, magnetic resonance imaging activity, and NEDA (No Evidence Disease Activity)-3 status in a Spanish population in a real-world setting. METHODS We conducted a multicenter prospective study of patie...
1 CitationsSource